Sands, B., Sandborn, W., Panaccione, R., O'Brien, C., Zhang, H., Johanns, J., Adedokun, O., Li, K., Peyrin-Biroulet, L., Van Assche, G., Danese, S., Targan, S., Abreu, M., Hisamatsu, T., Szapary, P., Marano, C., UNIFI Study Group: Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 381 (13), 1201-1214, 2019.
Sands, B., Peyrin-Biroulet, L., Loftus, E., Danese, S., Colombel, J., Törüner, M., Jonaitis, L., Abhyankar, B., Chen, J., Rogers, R., Lirio, R., Bornstein, J., Schreiber, S., VARSITY Study Group: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N. Engl. J. Med. 381 (13), 1215-1226, 2019.
Fickert, P., Hirschfield, G., Denk, G., Marschall, H., Altorjay, I., Farkkila, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., Schrumpf, E., Nevens, F., Trivedi, P., Reiter, F., Tornai, I., Halilbasic, E., Greinwald, R., Pröls, M., Manns, M., Trauner, M., European PSC norUDCA Study Group: norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J. Hepatol. 67 549-588, 2017.
Sands, B., Sandborn, W., Panaccione, R., O'Brien, C., Zhang, H., Johanns, J., Adedokun, O., Li, K., Peyrin-Biroulet, L., Van Assche, G., Danese, S., Targan, S., Abreu, M., Hisamatsu, T., Szapary, P., Marano, C., UNIFI Study Group: Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 381 (13), 1201-1214, 2019.
Sands, B., Peyrin-Biroulet, L., Loftus, E., Danese, S., Colombel, J., Törüner, M., Jonaitis, L., Abhyankar, B., Chen, J., Rogers, R., Lirio, R., Bornstein, J., Schreiber, S., VARSITY Study Group: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N. Engl. J. Med. 381 (13), 1215-1226, 2019.
Fickert, P., Hirschfield, G., Denk, G., Marschall, H., Altorjay, I., Farkkila, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., Schrumpf, E., Nevens, F., Trivedi, P., Reiter, F., Tornai, I., Halilbasic, E., Greinwald, R., Pröls, M., Manns, M., Trauner, M., European PSC norUDCA Study Group: norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J. Hepatol. 67 549-588, 2017.